(Seoul = Yonhap News) Reporter Gye Seung-Hyun = Pameokshin[208340]Announced on the 11th that it has signed a joint research contract with Legochem Biosciences on’PMC-403′, a candidate substance for normalizing blood vessels in the pre-clinical stage.
Both companies plan to evaluate the efficacy of solid cancer treatment and conduct preclinical studies by co-administering PMC-403, which is being developed by Pamexin, and an antibody-drug conjugate (ADC) candidate possessed by LegoChemBio.
PMC-403 is an antibody that activates an important factor in the regulation of angiogenesis (TIE2), and normalizes abnormal neovascularization.
With this mechanism, PMC-403 maximized efficacy by delivering immune cells and anticancer drugs to tumors through normalized blood vessels when administered alone or in combination with anticancer agents in preclinical colon cancer models.
PMC-403 also normalizes blood vessels damaged by vascular disease.
In August of last year, Pamexin announced that it will conduct a preclinical trial evaluating the therapeutic efficacy of PMC-403 for Systemic Capillary Leak Syndrome (SCLS) with the National Institute of Allergy and Infectious Diseases (NIAID), an agency affiliated with the National Institutes of Health.
Pamexin is currently developing PMC-403 as a treatment for vascular eye disease, senile maculopathy (AMD).
ADC is a substance that combines an antibody and a drug, and because of its excellent ability to kill cancer cells, various ADC treatments have already been released and used for solid cancer. If the drug is delivered to normal cells other than tumors, it can cause side effects.
Accordingly, the two companies are expected to reduce the dose by administering the two substances in combination to normalize damaged tumor neovascularization in the tumor microenvironment, and to deliver ADCs efficiently and tumor-specifically.
[파멥신 제공. 재판매 및 DB 금지]
Unauthorized reproduction-prohibition of redistribution>
2021/01/11 11:13 sent